Status: Enrolling
Investigator: Olga Waln
Study Coordinator: Titilayo Olubajo
Phone: 713.441.3780
This is a multi-center, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 4 weeks (with the exception of subjects on Primidone at baseline who will be allowed 6 weeks of screening to allow for safe ... Read more >
